CN103052398B - 稳定fsh - Google Patents

稳定fsh Download PDF

Info

Publication number
CN103052398B
CN103052398B CN201180037221.0A CN201180037221A CN103052398B CN 103052398 B CN103052398 B CN 103052398B CN 201180037221 A CN201180037221 A CN 201180037221A CN 103052398 B CN103052398 B CN 103052398B
Authority
CN
China
Prior art keywords
rfsh
fsh
salt
hcg
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180037221.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN103052398A (zh
Inventor
海伦·乌尓丽卡·舍格伦
海迪·路易斯·巴格尓
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferring BV
Original Assignee
Ferring BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring BV filed Critical Ferring BV
Priority to CN201510508334.4A priority Critical patent/CN105106939A/zh
Publication of CN103052398A publication Critical patent/CN103052398A/zh
Application granted granted Critical
Publication of CN103052398B publication Critical patent/CN103052398B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Fats And Perfumes (AREA)
CN201180037221.0A 2010-07-30 2011-07-28 稳定fsh Active CN103052398B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510508334.4A CN105106939A (zh) 2010-07-30 2011-07-28 稳定fsh

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10171428A EP2417982A1 (en) 2010-07-30 2010-07-30 Stabilization of gonadotropins
EP10171428.5 2010-07-30
PCT/EP2011/062986 WO2012013742A2 (en) 2010-07-30 2011-07-28 Stabilization of fsh

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510508334.4A Division CN105106939A (zh) 2010-07-30 2011-07-28 稳定fsh

Publications (2)

Publication Number Publication Date
CN103052398A CN103052398A (zh) 2013-04-17
CN103052398B true CN103052398B (zh) 2015-09-16

Family

ID=43216624

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201180037221.0A Active CN103052398B (zh) 2010-07-30 2011-07-28 稳定fsh
CN201510508334.4A Pending CN105106939A (zh) 2010-07-30 2011-07-28 稳定fsh

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201510508334.4A Pending CN105106939A (zh) 2010-07-30 2011-07-28 稳定fsh

Country Status (27)

Country Link
US (3) US8993732B2 (cg-RX-API-DMAC7.html)
EP (3) EP2417982A1 (cg-RX-API-DMAC7.html)
JP (3) JP5860047B2 (cg-RX-API-DMAC7.html)
KR (2) KR101991756B1 (cg-RX-API-DMAC7.html)
CN (2) CN103052398B (cg-RX-API-DMAC7.html)
AR (1) AR082776A1 (cg-RX-API-DMAC7.html)
AU (1) AU2011284702C1 (cg-RX-API-DMAC7.html)
BR (1) BR112013002312B1 (cg-RX-API-DMAC7.html)
CA (1) CA2805864A1 (cg-RX-API-DMAC7.html)
DK (1) DK2598160T3 (cg-RX-API-DMAC7.html)
ES (1) ES2623634T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20170386T1 (cg-RX-API-DMAC7.html)
HU (1) HUE033592T2 (cg-RX-API-DMAC7.html)
IL (2) IL223821A (cg-RX-API-DMAC7.html)
JO (1) JO3229B1 (cg-RX-API-DMAC7.html)
LT (1) LT2598160T (cg-RX-API-DMAC7.html)
MX (2) MX356951B (cg-RX-API-DMAC7.html)
NZ (2) NZ606366A (cg-RX-API-DMAC7.html)
PL (1) PL2598160T3 (cg-RX-API-DMAC7.html)
PT (1) PT2598160T (cg-RX-API-DMAC7.html)
RS (1) RS55772B1 (cg-RX-API-DMAC7.html)
RU (1) RU2574012C2 (cg-RX-API-DMAC7.html)
SA (1) SA114350786B1 (cg-RX-API-DMAC7.html)
SI (1) SI2598160T1 (cg-RX-API-DMAC7.html)
TW (1) TWI439283B (cg-RX-API-DMAC7.html)
WO (1) WO2012013742A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201209497B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) * 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
HK1223559A1 (zh) * 2013-11-12 2017-08-04 Cadila Healthcare Limited 用於促性腺激素的配方
CN105727260A (zh) * 2016-02-03 2016-07-06 华侨大学 一种卵泡刺激素的长效制剂
GB201603280D0 (en) 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
FR3083089A1 (fr) * 2018-06-29 2020-01-03 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
CA3084689A1 (fr) 2017-12-07 2019-06-13 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
SG11202005322RA (en) 2017-12-07 2020-07-29 Adocia Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid carrying carboxylate charges and hydrophobic radicals
FR3084584B1 (fr) * 2018-08-03 2020-11-06 Adocia Solution injectable a ph 7 comprenant du glucagon humain et un compose amphiphile porteur de radicaux hydrophobes
FR3084586B1 (fr) * 2018-08-03 2020-11-06 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un compose amphiphile porteur de radicaux hydrophobes
JP7425459B2 (ja) * 2019-10-11 2024-01-31 株式会社シノテスト 安定化されたhmgb1含有溶液

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0974359A2 (en) * 1998-07-23 2000-01-26 Eli Lilly And Company FSH and FSH variant formulations, products and methods
CN101272764A (zh) * 2005-09-27 2008-09-24 株式会社Lg生命科学 hFSH水制剂
CN102821782A (zh) * 2010-02-12 2012-12-12 印塔斯生物制药有限公司 促卵泡激素的液体配制品

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69524456T2 (de) 1995-03-21 2002-08-01 Applied Research Systems Flüssige hcg-formulierungen
NZ332968A (en) * 1996-05-29 2000-08-25 Bioxid Oy A controllably dissolvable silica-xerogel prepared via sol-gel
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
US20030166525A1 (en) * 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
ES2383994T3 (es) * 2004-04-07 2012-06-28 Ares Trading S.A. Formulación líquida de hormona del crecimiento
RS52106B (sr) * 2008-02-08 2012-08-31 Biogenerix Ag Tečni preparat fsh
TWI488640B (zh) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
CN101614748A (zh) * 2008-06-25 2009-12-30 上海新波生物技术有限公司 促卵泡激素时间分辨免疫荧光分析法及试剂盒
SG176963A1 (en) * 2009-06-22 2012-02-28 Amgen Inc Refolding proteins using a chemically controlled redox state
EP2417982A1 (en) * 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0974359A2 (en) * 1998-07-23 2000-01-26 Eli Lilly And Company FSH and FSH variant formulations, products and methods
CN101272764A (zh) * 2005-09-27 2008-09-24 株式会社Lg生命科学 hFSH水制剂
CN102821782A (zh) * 2010-02-12 2012-12-12 印塔斯生物制药有限公司 促卵泡激素的液体配制品

Also Published As

Publication number Publication date
EP3144010A1 (en) 2017-03-22
AU2011284702A1 (en) 2013-02-07
TW201208694A (en) 2012-03-01
MX341464B (es) 2016-08-22
JP2013532677A (ja) 2013-08-19
AU2011284702B2 (en) 2015-05-14
ZA201209497B (en) 2013-08-28
SA114350786B1 (ar) 2015-07-09
JP2016102127A (ja) 2016-06-02
LT2598160T (lt) 2017-04-10
RU2574012C2 (ru) 2016-01-27
NZ606366A (en) 2014-08-29
KR20130143692A (ko) 2013-12-31
RU2012157154A (ru) 2014-09-10
JP6522711B2 (ja) 2019-05-29
CN103052398A (zh) 2013-04-17
EP2598160A2 (en) 2013-06-05
WO2012013742A3 (en) 2012-04-19
JP2018048188A (ja) 2018-03-29
HUE033592T2 (hu) 2017-12-28
NZ628962A (en) 2016-01-29
AU2011284702C1 (en) 2015-09-03
MX2013000681A (es) 2013-02-27
US9463221B2 (en) 2016-10-11
PT2598160T (pt) 2017-03-30
WO2012013742A2 (en) 2012-02-02
KR101991756B1 (ko) 2019-06-21
ES2623634T3 (es) 2017-07-11
BR112013002312A2 (pt) 2018-03-20
JP5860047B2 (ja) 2016-02-16
US20170216405A1 (en) 2017-08-03
EP2598160B1 (en) 2017-02-22
KR101820115B1 (ko) 2018-01-18
RS55772B1 (sr) 2017-07-31
BR112013002312B1 (pt) 2021-09-21
JO3229B1 (ar) 2018-03-08
HRP20170386T1 (hr) 2017-05-05
AR082776A1 (es) 2013-01-09
IL249920A0 (en) 2017-03-30
EP2417982A1 (en) 2012-02-15
IL223821A (en) 2017-01-31
CN105106939A (zh) 2015-12-02
PL2598160T3 (pl) 2017-06-30
US20130210727A1 (en) 2013-08-15
SI2598160T1 (sl) 2017-07-31
CA2805864A1 (en) 2012-02-02
MX356951B (es) 2018-06-21
KR20180008916A (ko) 2018-01-24
DK2598160T3 (en) 2017-03-27
US8993732B2 (en) 2015-03-31
US20150265681A1 (en) 2015-09-24
TWI439283B (zh) 2014-06-01

Similar Documents

Publication Publication Date Title
JP6522711B2 (ja) Fshの安定化
US20250352621A1 (en) Stable liquid gonadotropin formulation
HK1184381A (en) Stabilization of fsh
HK1184381B (en) Stabilization of fsh

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant